Prothena Corporation plc (PRTA) Q4 2023 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Prothena Corporation Plc.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.469 -- 00:00:05.574 are in a listen-only mode. We will be facilitating a question and answer session 00:00:05.574 -- 00:00:10.639 towards the end of today's call. If at any time during the call you 00:00:10.639 -- 00:00:15.663 require assistance, please press star, then zero, and a 00:00:15.663 -- 00:00:20.628 coordinator will be happy to assist you. I would now like to turn the presentation over 00:00:20.628 -- 00:00:25.372 to Mark Johnson, Vice President of Investor Relations at Perthena. 00:00:25.372 -- 00:00:27.812 Please proceed. 00:00:30.523 -- 00:00:34.725 Thank you operator. Good afternoon and everyone and welcome to today's call to review 00:00:34.725 -- 00:00:39.747 Procena's business progress, fourth quarter and full year 2023 financial results 00:00:39.747 -- 00:00:44.610 and 2024 financial guidance. Please review the press release we issued earlier today, 00:00:44.610 -- 00:00:49.432 which is available on our website at Procena.com and is also attached to a form 8-K filed 00:00:49.432 -- 00:00:53.334 today with the SEC. In addition, we are using supplemental slides, which are available 00:00:53.334 -- 00:00:57.655 on our investor website events and presentation section. 00:00:58.027 -- 00:01:02.809 On today's call, Dr. Gene Kinney, our President and Chief Executive Officer, will provide 00:01:02.809 -- 00:01:07.150 opening remarks, including an overview of Prothena's corporate and development strategy. 00:01:07.150 -- 00:01:11.852 Then Brandon Smith, our Chief Operating Officer, will provide an update on our pre-commercial 00:01:11.852 -- 00:01:16.153 progress for our wholly-owned Britannimab program, which is in phase three for the treatment 00:01:16.153 -- 00:01:19.274 of patients with Mayo stage four ALN mitosis. 00:01:19.274 -- 00:01:...